{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T10:53:11Z","timestamp":1770720791503,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3601303"],"award-info":[{"award-number":["2022YFC3601303"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270316"],"award-info":[{"award-number":["82270316"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Current evidence is limited concerning the temporal impact of atrial fibrillation (AF) ablation timings on post-ablation outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients who experienced ablation in the CABANA trial were enrolled in our analysis. Diagnosis to ablation time (DAT) was calculated from the date when the initial AF episode was documented. The primary endpoint was a composite of death, disabling stroke, serious bleeding or cardiac arrest. Secondary end points included AF recurrence, all-cause mortality, and all-cause mortality or cardiovascular hospitalisation. Associations between DAT and post-ablation outcomes were evaluated by restricted cubic spline (RCS) curves based on Cox models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Out of 1145 patients (median age 67.0 years, interquartile range (IQR) 61.0\u201372.0; 36.7% female) included, 538 (47.0%) underwent early ablation (DAT\u2009\u2264\u20091 year), including 242 (45.0%) who received very early ablation (DAT\u2009\u2264\u200990\u00a0days). The overall median DAT was 423\u00a0days (IQR 118\u20131473). The L-shaped association was observed between DAT and the primary outcome (\n                      <jats:italic>P<\/jats:italic>\n                      for non-linear\u2009=\u20090.034). The lowest point was located at a DAT of approximately 1 to 3 years. For AF recurrences, the RCS curve rose progressively with increasing DAT (\n                      <jats:italic>P<\/jats:italic>\n                      for non-linear\u2009=\u20090.062), showing a reduced risk when DAT was less than 1 year. Effects of early ablation on the primary outcome favoured patients with initial AAD use (HR 0.86, 95% confidence interval (CI) 0.43\u20131.73 vs. HR 2.20, 95% CI\n                      <jats:italic>p<\/jats:italic>\n                      -interaction\u2009=\u20090.045).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The benefits of earlier ablation in reducing AF recurrence might not equate to improvements in post-ablation cardiovascular prognosis. Timely treatment combining AADs and ablation may provide additional cardiovascular benefits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov Identifier: NCT00911508.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-026-04615-3","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T10:33:20Z","timestamp":1768214000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of diagnosis to ablation time on clinical outcomes in patients with atrial fibrillation: post hoc analysis of the CABANA trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Manlin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caihua","family":"Sang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzeng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas L.","family":"Packer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changsheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"4615_CR1","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","volume":"14","author":"GYH Lip","year":"2017","unstructured":"Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol. 2017;14:627\u20138.","journal-title":"Nat Rev Cardiol"},{"key":"4615_CR2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1707855","volume":"378","author":"NF Marrouche","year":"2018","unstructured":"Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378:417\u201327.","journal-title":"N Engl J Med"},{"key":"4615_CR3","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","volume":"383","author":"P Kirchhof","year":"2020","unstructured":"Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383:1305\u201316.","journal-title":"N Engl J Med"},{"key":"4615_CR4","doi-asserted-by":"publisher","first-page":"e007414","DOI":"10.1161\/CIRCEP.119.007414","volume":"12","author":"ZUA Asad","year":"2019","unstructured":"Asad ZUA, Yousif A, Khan MS, Al-Khatib SM, Stavrakis S. Catheter ablation versus medical therapy for atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Circ Arrhythm Electrophysiol. 2019;12:e007414.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"4615_CR5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1001\/jamacardio.2021.0852","volume":"6","author":"MK Turagam","year":"2021","unstructured":"Turagam MK, Musikantow D, Whang W, Koruth JS, Miller MA, Langan MN, et al. Assessment of catheter ablation or antiarrhythmic drugs for first-line therapy of atrial fibrillation: a meta-analysis of randomized clinical trials. JAMA Cardiol. 2021;6:697\u2013705.","journal-title":"JAMA Cardiol"},{"key":"4615_CR6","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2029554","volume":"384","author":"OM Wazni","year":"2021","unstructured":"Wazni OM, Dandamudi G, Sood N, Hoyt R, Tyler J, Durrani S, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med. 2021;384:316\u201324.","journal-title":"N Engl J Med"},{"key":"4615_CR7","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/eurheartj\/ehx466","volume":"39","author":"JL Pallisgaard","year":"2018","unstructured":"Pallisgaard JL, Gislason GH, Hansen J, Johannessen A, Torp-Pedersen C, Rasmussen PV, et al. Temporal trends in atrial fibrillation recurrence rates after ablation between 2005 and 2014: a nationwide Danish cohort study. Eur Heart J. 2018;39:442\u20139.","journal-title":"Eur Heart J"},{"key":"4615_CR8","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1093\/europace\/eur398","volume":"14","author":"CA Goudis","year":"2012","unstructured":"Goudis CA, Kallergis EM, Vardas PE. Extracellular matrix alterations in the atria: insights into the mechanisms and perpetuation of atrial fibrillation. Europace. 2012;14:623\u201330.","journal-title":"Europace"},{"key":"4615_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.pbiomolbio.2008.02.019","volume":"97","author":"J Eckstein","year":"2008","unstructured":"Eckstein J, Verheule S, de Groot NM, Allessie M, Schotten U. Mechanisms of perpetuation of atrial fibrillation in chronically dilated atria. Prog Biophys Mol Biol. 2008;97:435\u201351.","journal-title":"Prog Biophys Mol Biol"},{"key":"4615_CR10","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.hrthm.2018.10.022","volume":"16","author":"S Blum","year":"2019","unstructured":"Blum S, Meyre P, Aeschbacher S, Berger S, Auberson C, Briel M, et al. Incidence and predictors of atrial fibrillation progression: a systematic review and meta-analysis. Heart Rhythm. 2019;16:502\u201310.","journal-title":"Heart Rhythm"},{"key":"4615_CR11","doi-asserted-by":"publisher","unstructured":"Shen T, Li M, Zhao M, Jiang C, Wang Z, Zhao Z, et al. The impact of atrial remodeling on the efficacy of catheter ablation in reducing cardiovascular risk in atrial fibrillation: results from the CABANA trial. Heart Rhythm. 2025. https:\/\/doi.org\/10.1016\/j.hrthm.2025.04.019.","DOI":"10.1016\/j.hrthm.2025.04.019"},{"key":"4615_CR12","doi-asserted-by":"publisher","first-page":"e013261","DOI":"10.1161\/CIRCEP.124.013261","volume":"18","author":"AM Amin","year":"2025","unstructured":"Amin AM, Elbenawi H, Khan U, Almaadawy O, Turkmani M, Abdelmottaleb W, et al. Impact of diagnosis to ablation time on recurrence of atrial fibrillation and clinical outcomes after catheter ablation: a systematic review and meta-analysis with reconstructed time-to-event data. Circ Arrhythm Electrophysiol. 2025;18:e013261.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"4615_CR13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/europace\/euw426","volume":"20","author":"Y De Greef","year":"2018","unstructured":"De Greef Y, Schwagten B, Chierchia GB, de Asmundis C, Stockman D, Buysschaert I. Diagnosis-to-ablation time as a predictor of success: early choice for pulmonary vein isolation and long-term outcome in atrial fibrillation: results from the Middelheim-PVI registry. Europace. 2018;20:589\u201395.","journal-title":"Europace"},{"key":"4615_CR14","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1093\/europace\/euaa383","volume":"23","author":"M Lycke","year":"2021","unstructured":"Lycke M, Kyriakopoulou M, El Haddad M, Wielandts JY, Hilfiker G, Almorad A, et al. Predictors of recurrence after durable pulmonary vein isolation for paroxysmal atrial fibrillation. Europace. 2021;23:861\u20137.","journal-title":"Europace"},{"key":"4615_CR15","doi-asserted-by":"publisher","first-page":"e012697","DOI":"10.1161\/CIRCEP.123.012697","volume":"17","author":"TJ Bunch","year":"2024","unstructured":"Bunch TJ, Poole JE, Silverstein AP, Lee KL, Al-Khalidi HR, Hindricks G, et al. Prognostic impact of sinus rhythm in atrial fibrillation patients: separating rhythm outcomes from randomized strategy findings from the CABANA trial. Circ Arrhythm Electrophysiol. 2024;17:e012697.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"4615_CR16","doi-asserted-by":"publisher","first-page":"e032722","DOI":"10.1161\/JAHA.123.032722","volume":"13","author":"J Tonnesen","year":"2024","unstructured":"Tonnesen J, Ruwald MH, Pallisgaard J, Rasmussen PV, Johannessen A, Hansen J, et al. Lower recurrence rates of atrial fibrillation and MACE events after early compared to late ablation: a Danish nationwide register study. J Am Heart Assoc. 2024;13:e032722.","journal-title":"J Am Heart Assoc"},{"key":"4615_CR17","doi-asserted-by":"crossref","unstructured":"Kwon S, Lee SR, Choi EK, Kim B, Han KD, Choi J, et al. Benefits of early catheter ablation in patients with atrial fibrillation: a nationwide cohort study. JACC Clin Electrophysiol. 2025;11:956\u201365.","DOI":"10.1016\/j.jacep.2024.12.023"},{"key":"4615_CR18","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jama.2019.0693","volume":"321","author":"DL Packer","year":"2019","unstructured":"Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321:1261\u201374.","journal-title":"JAMA"},{"key":"4615_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ahj.2018.02.015","volume":"199","author":"DL Packer","year":"2018","unstructured":"Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Moretz K, et al. Catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation (CABANA) trial: study rationale and design. Am Heart J. 2018;199:192\u20139.","journal-title":"Am Heart J"},{"key":"4615_CR20","unstructured":"CABANA (Catheter Ablation vs. Antiarrhythmic Drug Therapy for Atrial fibrillation). BioLINCC, National Heart, Lung, and Blood Institute. https:\/\/biolincc.nhlbi.nih.gov\/home. Accessed 6 Oct 2023. (BioLINCC Request Number 15664; Clinical Trial unique identifier NCT00911508)"},{"key":"4615_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/jnnp-2016-315457","volume":"89","author":"Y Mayasi","year":"2018","unstructured":"Mayasi Y, Helenius J, McManus DD, Goddeau RP, Jun-O\u2019Connell AH, Moonis M, et al. Atrial fibrillation is associated with anterior predominant white matter lesions in patients presenting with embolic stroke. J Neurol Neurosurg Psychiatry. 2018;89:6\u201313.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4615_CR22","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1016\/j.jacc.2020.04.065","volume":"75","author":"JE Poole","year":"2020","unstructured":"Poole JE, Bahnson TD, Monahan KH, Johnson G, Rostami H, Silverstein AP, et al. Recurrence of atrial fibrillation after catheter ablation or antiarrhythmic drug therapy in the CABANA Trial. J Am Coll Cardiol. 2020;75:3105\u201318.","journal-title":"J Am Coll Cardiol"},{"key":"4615_CR23","doi-asserted-by":"publisher","first-page":"100967","DOI":"10.1016\/j.lanepe.2024.100967","volume":"43","author":"K Teppo","year":"2024","unstructured":"Teppo K, Lip GYH, Airaksinen KEJ, Halminen O, Haukka J, Putaala J, et al. Comparing CHA(2)DS(2)-VA and CHA(2)DS(2)-VASc scores for stroke risk stratification in patients with atrial fibrillation: a temporal trends analysis from the retrospective Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) cohort. Lancet Reg Health Eur. 2024;43:100967.","journal-title":"Lancet Reg Health Eur"},{"key":"4615_CR24","doi-asserted-by":"publisher","first-page":"e008128","DOI":"10.1161\/CIRCEP.119.008128","volume":"13","author":"DS Chew","year":"2020","unstructured":"Chew DS, Black-Maier E, Loring Z, Noseworthy PA, Packer DL, Exner DV, et al. Diagnosis-to-ablation time and recurrence of atrial fibrillation following catheter ablation: a systematic review and meta-analysis of observational studies. Circ Arrhythm Electrophysiol. 2020;13:e008128.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"4615_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/diseases12020038","volume":"12","author":"A Nastasa","year":"2024","unstructured":"Nastasa A, Sahloul MH, Iorgulescu C, Bogdan S, Scarlatescu A, Paja S, et al. The association between diagnosis-to-ablation time and the recurrence of atrial fibrillation: a retrospective cohort study. Diseases. 2024;12:38.","journal-title":"Diseases"},{"key":"4615_CR26","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.jacep.2023.07.008","volume":"9","author":"Y De Greef","year":"2023","unstructured":"De Greef Y, Bogaerts K, Sofianos D, Buysschaert I. Impact of diagnosis-to-ablation time on AF recurrence: pronounced the first 3 years, irrelevant thereafter. JACC Clin Electrophysiol. 2023;9:2263\u201372.","journal-title":"JACC Clin Electrophysiol"},{"key":"4615_CR27","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0008-6363(02)00258-4","volume":"54","author":"M Allessie","year":"2002","unstructured":"Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res. 2002;54:230\u201346.","journal-title":"Cardiovasc Res"},{"key":"4615_CR28","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1001\/jama.2014.3","volume":"311","author":"NF Marrouche","year":"2014","unstructured":"Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA. 2014;311:498\u2013506.","journal-title":"JAMA"},{"key":"4615_CR29","doi-asserted-by":"publisher","first-page":"e003669","DOI":"10.1161\/CIRCEP.115.003669","volume":"9","author":"AA Hussein","year":"2016","unstructured":"Hussein AA, Saliba WI, Barakat A, Bassiouny M, Chamsi-Pasha M, Al-Bawardy R, et al. Radiofrequency ablation of persistent atrial fibrillation: diagnosis-to-ablation time, markers of pathways of atrial remodeling, and outcomes. Circ Arrhythm Electrophysiol. 2016;9:e003669.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"4615_CR30","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.jacc.2008.11.054","volume":"53","author":"MK Stiles","year":"2009","unstructured":"Stiles MK, John B, Wong CX, Kuklik P, Brooks AG, Lau DH, et al. Paroxysmal lone atrial fibrillation is associated with an abnormal atrial substrate: characterizing the \u201csecond factor.\u201d J Am Coll Cardiol. 2009;53:1182\u201391.","journal-title":"J Am Coll Cardiol"},{"key":"4615_CR31","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1111\/jce.15002","volume":"32","author":"T Takamiya","year":"2021","unstructured":"Takamiya T, Nitta J, Inaba O, Sato A, Inamura Y, Murata K, et al. Impact of diagnosis-to-ablation time on non-pulmonary vein triggers and ablation outcomes in persistent atrial fibrillation. J Cardiovasc Electrophysiol. 2021;32:1251\u20138.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"4615_CR32","doi-asserted-by":"publisher","first-page":"euae265","DOI":"10.1093\/europace\/euae265","volume":"26","author":"VM La Fazia","year":"2024","unstructured":"La Fazia VM, Pierucci N, Schiavone M, Compagnucci P, Mohanty S, Gianni C, et al. Comparative effects of different power settings for achieving transmural isolation of the left atrial posterior wall with radiofrequency energy. Europace. 2024;26:euae265.","journal-title":"Europace"},{"key":"4615_CR33","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1093\/eurheartj\/ehad247","volume":"44","author":"JM Kalman","year":"2023","unstructured":"Kalman JM, Al-Kaisey AM, Parameswaran R, Hawson J, Anderson RD, Lim M, et al. Impact of early vs. delayed atrial fibrillation catheter ablation on atrial arrhythmia recurrences. Eur Heart J. 2023;44:2447\u201354.","journal-title":"Eur Heart J"},{"key":"4615_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijcard.2019.03.036","volume":"291","author":"T Kawaji","year":"2019","unstructured":"Kawaji T, Shizuta S, Yamagami S, Aizawa T, Komasa A, Yoshizawa T, et al. Early choice for catheter ablation reduced readmission in management of atrial fibrillation: impact of diagnosis-to-ablation time. Int J Cardiol. 2019;291:69\u201376.","journal-title":"Int J Cardiol"},{"key":"4615_CR35","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.hrthm.2013.05.013","volume":"10","author":"TJ Bunch","year":"2013","unstructured":"Bunch TJ, May HT, Bair TL, Johnson DL, Weiss JP, Crandall BG, et al. Increasing time between first diagnosis of atrial fibrillation and catheter ablation adversely affects long-term outcomes. Heart Rhythm. 2013;10:1257\u201362.","journal-title":"Heart Rhythm"},{"key":"4615_CR36","doi-asserted-by":"publisher","first-page":"e038832","DOI":"10.1161\/JAHA.124.038832","volume":"14","author":"S Li","year":"2025","unstructured":"Li S, Zhang J, Zuo S, Wang J, Lai Y, Li M, et al. Patterns of postablation recurrence and adverse cardiovascular outcomes in patients with atrial fibrillation. J Am Heart Assoc. 2025;14:e038832.","journal-title":"J Am Heart Assoc"},{"key":"4615_CR37","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1161\/CIRCULATIONAHA.121.055297","volume":"145","author":"TD Bahnson","year":"2022","unstructured":"Bahnson TD, Giczewska A, Mark DB, Russo AM, Monahan KH, Al-Khalidi HR, et al. Association between age and outcomes of catheter ablation versus medical therapy for atrial fibrillation: results from the CABANA trial. Circulation. 2022;145:796\u2013804.","journal-title":"Circulation"},{"key":"4615_CR38","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.120.050991","volume":"143","author":"DL Packer","year":"2021","unstructured":"Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA, et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. Circulation. 2021;143:1377\u201390.","journal-title":"Circulation"},{"key":"4615_CR39","doi-asserted-by":"crossref","unstructured":"Dhont S, Bertrand PB, Erzeel J, Deferm S, Pison L, Vandervoort PM, et al. The interaction between atrial fibrillation and mitral regurgitation: Insights from the CABANA randomized clinical trial. Eur J Heart Fail. 2025;27:1500\u20137.","DOI":"10.1002\/ejhf.3668"},{"key":"4615_CR40","doi-asserted-by":"publisher","first-page":"euae237","DOI":"10.1093\/europace\/euae237","volume":"26","author":"R Krittayaphong","year":"2024","unstructured":"Krittayaphong R, Treewaree S, Lip GYH. Components of the atrial fibrillation better care pathway for holistic care of patients with atrial fibrillation: a win ratio analysis from the COOL-AF registry. Europace. 2024;26:euae237.","journal-title":"Europace"},{"key":"4615_CR41","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1056\/NEJMoa1113566","volume":"367","author":"J Cosedis Nielsen","year":"2012","unstructured":"Cosedis Nielsen J, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, Kongstad O, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med. 2012;367:1587\u201395.","journal-title":"N Engl J Med"},{"key":"4615_CR42","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2029980","volume":"384","author":"JG Andrade","year":"2021","unstructured":"Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, Champagne J, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med. 2021;384:305\u201315.","journal-title":"N Engl J Med"},{"key":"4615_CR43","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1093\/eurheartj\/ehu354","volume":"35","author":"S Darkner","year":"2014","unstructured":"Darkner S, Chen X, Hansen J, Pehrson S, Johannessen A, Nielsen JB, et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). Eur Heart J. 2014;35:3356\u201364.","journal-title":"Eur Heart J"},{"key":"4615_CR44","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/eurheartj\/ehx666","volume":"39","author":"M Duytschaever","year":"2018","unstructured":"Duytschaever M, Demolder A, Phlips T, Sarkozy A, El Haddad M, Taghji P, et al. PulmOnary vein isolation with vs. without continued antiarrhythmic drug trEatment in subjects with recurrent atrial fibrillation (POWDER AF): results from a multicentre randomized trial. Eur Heart J. 2018;39:1429\u201337.","journal-title":"Eur Heart J"},{"key":"4615_CR45","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jacep.2024.11.020","volume":"11","author":"S Saksena","year":"2025","unstructured":"Saksena S, Ken-Opurum J, McKindley DS, Preblick R, Rashkin J, Aldaas OM, et al. Arrhythmia recurrence and rhythm control strategies after catheter ablation of newly diagnosed atrial fibrillation (ARRC-AF study). JACC Clin Electrophysiol. 2025;11:763\u201375.","journal-title":"JACC Clin Electrophysiol"},{"key":"4615_CR46","doi-asserted-by":"crossref","unstructured":"Arbelo E, Brugada J, Lundqvist CB, Laroche C, Kautzner J, Pokushalov E, et al. Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry. Eur Heart J. 2017;38:1303\u201316.","DOI":"10.1093\/eurheartj\/ehw564"},{"key":"4615_CR47","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1161\/CIRCULATIONAHA.119.042622","volume":"140","author":"JG Andrade","year":"2019","unstructured":"Andrade JG, Champagne J, Dubuc M, Deyell MW, Verma A, Macle L, et al. Cryoballoon or radiofrequency ablation for atrial fibrillation assessed by continuous monitoring: a randomized clinical trial. Circulation. 2019;140:1779\u201388.","journal-title":"Circulation"},{"key":"4615_CR48","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/jce.13047","volume":"27","author":"R Cardoso","year":"2016","unstructured":"Cardoso R, Mendirichaga R, Fernandes G, Healy C, Lambrakos LK, Viles-Gonzalez JF, et al. Cryoballoon versus radiofrequency catheter ablation in atrial fibrillation: a meta-analysis. J Cardiovasc Electrophysiol. 2016;27:1151\u20139.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"4615_CR49","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/NEJMoa1602014","volume":"374","author":"KH Kuck","year":"2016","unstructured":"Kuck KH, Brugada J, F\u00fcrnkranz A, Metzner A, Ouyang F, Chun KR, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med. 2016;374:2235\u201345.","journal-title":"N Engl J Med"},{"key":"4615_CR50","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1093\/eurheartj\/ehw285","volume":"37","author":"KH Kuck","year":"2016","unstructured":"Kuck KH, F\u00fcrnkranz A, Chun KR, Metzner A, Ouyang F, Schl\u00fcter M, et al. Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial. Eur Heart J. 2016;37:2858\u201365.","journal-title":"Eur Heart J"},{"key":"4615_CR51","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.3390\/jcm13102980","volume":"13","author":"N Pierucci","year":"2024","unstructured":"Pierucci N, Mariani MV, Laviola D, Silvetti G, Cipollone P, Vernile A, et al. Pulsed field energy in atrial fibrillation ablation: from physical principles to clinical applications. J Clin Med. 2024;13:2980.","journal-title":"J Clin Med"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04615-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04615-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04615-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:05:22Z","timestamp":1770649522000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04615-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4615"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04615-3","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This analysis was waived for ethical approval by the University of Liverpool Research Integrity and Ethics (Reference 15107). Patient consent was not required for this secondary data analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GYHL is a consultant and speaker for Bristol Myers Squibb\/Pfizer, Boehringer Ingelheim, Anthos, and Daiichi Sankyo; no fees personally. Dr Lip is co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union\u2019s Horizon 2020 research and innovation program under grant agreement No. 899871. CSM has received honoraria for presentations from AstraZeneca, Bayer Healthcare, Boehringer Ingelheim, Bristol-Myers Squibb, Johnson & Johnson, and Pfizer. JZD has received honoraria for presentations from Johnson & Johnson. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}